Fulgent Genetics

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Fulgent Genetics surpasses revenue targets, eyes precision medicine growth

Fulgent Genetics delivered strong financial performance in 2022, exceeding revenue guidance and positioning for continued growth in 2023 across key business segments.
The company's strategic focus on precision medicine, oncology, and pharma services, coupled with a robust cash position, sets the stage for future expansion and innovation.
Challenges in margin improvement and reimbursement highlight areas for operational refinement, while opportunities in acquisitions and menu expansion offer avenues for sustained growth.

Fulgent Genetics reports robust Q1 revenue growth and strategic advancements

Fulgent Genetics delivered strong revenue growth in Q1 2023, with a focus on core business strength and promising developments in key drug candidates and business segments.
While facing challenges in operational efficiency and negative Adjusted EBITDA, the company maintains a strong cash position and is optimistic about future opportunities.
Strategic acquisitions, market expansion, and continued margin improvement are key areas of focus for Fulgent Genetics to drive sustained growth and profitability.

Fulgent Genetics reports record Q2 revenue and advances in cancer treatment

Fulgent Genetics (FLGT) delivered a strong performance in Q2 2023, with record core revenue and promising developments in cancer treatment.
The company's focus on innovation, operational efficiency, and margin improvement underscores a commitment to sustainable growth.
While facing challenges in cost management and competitive dynamics, Fulgent Genetics is well-positioned to capitalize on opportunities through technology and strategic initiatives.

Fulgent Genetics reports robust Q3 earnings, eyes growth in precision diagnostics

Fulgent Genetics demonstrated solid financial performance in Q3 2023, with strong core revenue and improved gross margins. The company continues to focus on precision diagnostics and therapeutic development, presenting growth opportunities. Challenges include fluctuations in Pharma services revenue and COVID-19 testing demand.

Fulgent Genetics surpasses Q4 revenue targets, eyes FDA regulatory landscape

Fulgent Genetics delivered strong Q4 results, exceeding revenue guidance and showcasing growth in core revenue.
The company faces challenges in BioPharma Services and Anatomic Pathology but is investing in operations and AI for improvement.
Opportunities lie in Precision Diagnostics growth, market share gains in carrier screening, and adapting to FDA oversight of laboratory developed tests.
Management's confidence in quality systems and readiness to pursue FDA approval for high-risk tests position Fulgent Genetics for regulatory changes.

Fulgent Genetics excels in Q1 2024 with strong revenue growth

Fulgent Genetics delivered strong Q1 results driven by precision diagnostics and therapeutic development progress.
While facing challenges in managing expenses, the company showcased financial discipline and innovation in new product launches.
With a focus on improving margins and capturing market opportunities, Fulgent Genetics aims for continued growth and profitability in 2024.

Fulgent Genetics reports robust Q2 revenue, invests in innovative treatments

Fulgent Genetics demonstrated solid revenue performance in Q2, driven by core business growth in key segments.
While facing profitability challenges, the company continues to invest in innovative treatments and technology.
Maintaining a strong cash position and focusing on strategic growth areas position Fulgent Genetics for future success.
Balancing cost management with revenue growth will be crucial for the company's financial health and long-term sustainability.

Fulgent Genetics reports robust Q3 earnings, eyes strategic growth opportunities

Fulgent Genetics demonstrated solid revenue growth and financial stability in Q3 2024.
The company's focus on precision diagnostics and therapeutic development shows promise for future growth.
Challenges lie in maintaining margins, managing expenses, and optimizing the VA contract's impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in El Monte, CA.

TEMPLE CITY, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its third quarter 2020 financial results after the market closes on Monday November 9, 2020. The company's Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthuis will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

Fulgent Genetics to Announce Third Quarter 2020 Financial Results on Monday November 9, 2020

Endurance International Group

Limelight Networks

Growth-focused investors may want to consider investing in the following small-cap stocks, as they represent companies whose trailing 12-month pro forma earnings per share (EPS) improved dramatically on a year-over-year basis.

A Trio of Fast-Growing Small Caps

Fulgent Genetics will provide routine RT-PCR testing for the ODRC’s approximately 14,000 employees Fulgent Genetics will provide routine RT-PCR testing for the ODRC’s approximately 14,000 employees

Fulgent Genetics Announces Partnership with Ohio Department of Rehabilitation and Correction for COVID-19 Testing

Miami-Dade switches to the Fulgent RT-PCR test and Community Testing Platform Miami-Dade switches to the Fulgent RT-PCR test and Community Testing Platform

Fulgent Genetics, Miami-Dade County Partner on COVID-19 testing

Fulgent Genetics (FLGT) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.

Strength Seen in Fulgent Genetics (FLGT): Stock Soars 11.6%

TEMPLE CITY, Calif., Sept.  04, 2020  (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, and Chief Commercial Officer Brandon Perthuis are scheduled to virtually participate in the H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020. These representatives of the company will host a presentation beginning at 1:00 p.m. ET.

Fulgent Genetics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference

New York City will use the company's COVID-19 test in its public school system.

Here's Why Fulgent Genetics Is Skyrocketing 16.7% Today

COVID-19 and Influenza A/B will be run on single nasal swab at no additional cost to patients COVID-19 and Influenza A/B will be run on single nasal swab at no additional cost to patients

Fulgent Genetics Adds Influenza A and Influenza B to all COVID-19 Tests

Test and Trace (T2) Program will use Picture by Fulgent at-home test for hundreds of thousands of students to help ensure a safe return to school Test and Trace (T2) Program will use Picture by Fulgent at-home test for hundreds of thousands of students to help ensure a safe return to school

Fulgent Genetics, New York City Health and Hospitals Partner on Large-Scale Back-to-School COVID-19 Testing

Fluidigm

The Nasdaq Composite failed to hit a record for the first time in a week.

Nasdaq Falls 40; Fulgent, Fluidigm Collapse on COVID-19 Competition

Abbott's announcement of a new 15-minute COVID-19 test threatens recent revenue growth.

Why Fulgent Genetics Is Crashing Today

FULGENT GENETIC (FLGT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Earnings Estimates Moving Higher for FULGENT GENETIC (FLGT): Time to Buy?

Fulgent Genetics stock has gained 253% so far this year. Strong growth and a reasonable valuation suggest the rally will continue.

Why Fulgent Genetics Stock Can Keep Soaring

The demand for Covid-19 testing kits has been strong, and that's bullish for Fulgent Genetics stock, but don't just buy it at any price.
The post Let High Flyer Fulgent Genetics Take a Breather Before Dipping In appeared first on InvestorPlace.

Let High Flyer Fulgent Genetics Take a Breather Before Dipping In

It's only a relatively small player in the rapidly expanding field of genetic testing, but this is changing in front of our eyes.

Fulgent's Epic Ramp In Testing Is One For The Ages

CLIA-Certified Laboratory will Increase Testing Capacity  Raising FY20 Revenue Guidance to $135 Million from $120 Million

Fulgent Genetics Announces Expansion into Houston, TX

Fulgent Genetics, Inc. (FLGT) CEO Ming Hsieh on Q2 2020 Results - Earnings Call Transcript

FULGENT GENETIC (FLGT) delivered earnings and revenue surprises of 1600.00% and 18.91%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

FULGENT GENETIC (FLGT) Q2 Earnings and Revenues Beat Estimates

Fulgent Genetics Reports Record Second Quarter 2020 Financial Results

TEMPLE CITY, Calif., July  14, 2020  (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its second quarter 2020 financial results after the market closes on Tuesday August 4, 2020. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthuis will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

Fulgent Genetics to Announce Second Quarter 2020 Financial Results on Tuesday August 4, 2020

Fulgent Genetics has received Emergency Use Authorization from the FDA to provide at-home testing services for SARS-CoV-2, the virus that causes COVID-19 Fulgent Genetics has received Emergency Use Authorization from the FDA to provide at-home testing services for SARS-CoV-2, the virus that causes COVID-19

Fulgent Genetics Announces FDA Authorization and Launch of At-Home Testing Service for COVID-19 

The company's strong growth is likely to suffer as a result of the pandemic, but we think this is only a temporary blip.

Fulgent's COVID-19 Tests Are Ramping Fast, But Their Other Tests Are Suffering

TEMPLE CITY, Calif., May  18, 2020  (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a provider of comprehensive genetic testing solutions, today announced that its subsidiary, Fulgent Therapeutics, LLC, has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its RT-PCR test for the detection of SARS-CoV-2, the virus that causes COVID-19, using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs). The company is offering end-to-end processing, analysis and reporting for its COVID-19 tests through its BSL-2, CLIA-certified lab in Temple City, California.

Fulgent Genetics Receives Emergency Use Authorization from the FDA for its RT-PCR Test for Detection of SARS-CoV-2, the Virus that Causes COVID-19

Fulgent Genetics, Inc. (FLGT) CEO Ming Hsieh on Q1 2020 Results - Earnings Call Transcript

FULGENT GENETIC (FLGT) delivered earnings and revenue surprises of 0.00% and 0.82%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

News for Fulgent Genetics Stock (FLGT)